Business
Moderna MRNA earnings Q3 2021
Moderna’s signal is seen exterior of their headquarters in Cambridge, MA on March 11, 2021.
Boston Globe | Getty Photos
Moderna shares fell 8% on Thursday after it lower its Covid-19 vaccine gross sales forecast for the 12 months to between $15 billion and $18 billion from $20 billion.
This can be a creating story. Please test again for updates.